Pentoxifylline

Generic Name: Pentoxifylline

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈N_₄O_₃

CAS Number: 6493-05-6

Unique Ingredient Identifier: SD6QCT3TSU

Background: Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties. Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated...

Indication: Pentoxifylline is indicated for the treatment of intermittent claudication in patients with chronic occlusive arterial disease. Pentoxifylline may improve limb function and reduce symptoms but cannot replace other therapies such as surgical bypass or removal of vascular obstructions.

Associated Conditions: Intermittent Claudication, Venous Leg Ulcer (VLU), Severe alcoholic liver disease

Associated Therapies: -

Clinical Trials

Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19

Not Applicable

Completed

Conditions: Pneumonia, Viral
Covid19
ARDS
Oxidative Stress

Interventions: Drug: Vitamin C
Drug: Vitamin E
Drug: Melatonin
Drug: N-acetyl cysteine
Drug: Pentoxifylline

First Posted Date: 2020-09-30

Last Posted Date: 2021-05-21

Lead Sponsor: Unidad Temporal COVID-19 en Centro Citibanamex

Target Recruit Count: 110

Registration Number: NCT04570254

Locations: 🇲🇽
Unidad Temporal COVID-19 en Centro Citibanamex, Mexico City, Mexico

Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients

Phase 1

Withdrawn

Conditions: COVID

Interventions: Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2020-06-16

Last Posted Date: 2023-01-18

Lead Sponsor: Sadat City University

Registration Number: NCT04433988

Locations: 🇪🇬
Faculty of Medicine, Shibīn Al Kawm, Egypt

Effect of Pentoxifylline on Endothelial Dysfunction in Patients With Acute Coronary Syndrome

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Pentoxifylline

First Posted Date: 2020-04-29

Last Posted Date: 2022-09-07

Lead Sponsor: Ain Shams University

Target Recruit Count: 43

Registration Number: NCT04367935

Locations: 🇪🇬
Ain Shams University Hospitals, Cairo, Egypt

Pentoxifylline Dose Optimization in Neonatal Sepsis

Phase 3

Completed

Conditions: Neonatal Late Onset Sepsis

Interventions: Drug: Pentoxifylline

First Posted Date: 2019-11-06

Last Posted Date: 2024-08-09

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 30

Registration Number: NCT04152980

Locations: 🇵🇱
University Hospital Poznan, Poznan, Poland
🇳🇱
Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands

Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Pentoxifylline
Drug: Placebo oral tablet

First Posted Date: 2019-09-18

Last Posted Date: 2022-10-25

Lead Sponsor: Sadat City University

Target Recruit Count: 80

Registration Number: NCT04094207

Locations: 🇪🇬
Faculty of Medicine, Shibīn Al Kawm, Egypt

Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers

Phase 2

Completed

Conditions: Behçet Disease Affecting Oral Mucosa

Interventions: Drug: Colchicine
Drug: Pentoxifylline

First Posted Date: 2019-03-25

Last Posted Date: 2023-08-03

Lead Sponsor: Ipekyolu Ilac Ltd. Sti

Target Recruit Count: 41

Registration Number: NCT03888846

Locations: 🇹🇷
Istanbul Universitesi-Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Anabilim Dalı-Romatoloji, Istanbul, Turkey

Pentoxifylline in Lupus Nephritis

Phase 4

Withdrawn

Conditions: Lupus Nephritis

Interventions: Drug: Placebos
Drug: Pentoxifylline

First Posted Date: 2019-03-01

Last Posted Date: 2021-02-02

Lead Sponsor: MetroHealth Medical Center

Registration Number: NCT03859570

Locations: 🇺🇸
Metrohealth Medical Center, Cleveland, Ohio, United States

Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PCS499
Drug: Trental

First Posted Date: 2019-02-11

Last Posted Date: 2019-02-12

Lead Sponsor: Processa Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT03836222

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

Phase 2

Completed

Conditions: Erectile Dysfunction, CTCAE
Male Erectile Disorder
Prostate Adenocarcinoma
Impotence

Interventions: Drug: Atorvastatin
Drug: Pentoxifylline
Dietary Supplement: Vitamin E Compound

First Posted Date: 2019-02-05

Last Posted Date: 2023-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT03830164

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients?

Phase 2

Completed

Conditions: Anemia of Chronic Kidney Disease

Interventions: Drug: Pentoxifylline

First Posted Date: 2018-11-06

Last Posted Date: 2018-11-08

Lead Sponsor: Tanta University

Target Recruit Count: 57

Registration Number: NCT03731741

Locations: 🇪🇬
Tanta university hospital, Tanta, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy